<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Omentin-1 and risk of myocardial infarction and stroke: Results from the EPIC-Potsdam cohort study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-02">2 June 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Juliane</forename><surname>Menzel</surname></persName>
							<email>juliane.menzel@dife.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition PotsdameRehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Research Group Cardiovascular Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition Potsdam-Rehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute for Social Medicine, Epidemiology and Health Economics</orgName>
								<orgName type="institution">Charit e University Medical Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">German Center for Diabetes Research (DZD)</orgName>
								<address>
									<settlement>München-Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Romina</forename><surname>Di Giuseppe</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Research Group Cardiovascular Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition Potsdam-Rehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Institute of Epidemiology</orgName>
								<orgName type="institution">Christian-Albrechts University Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ronald</forename><surname>Biemann</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute for Clinical Chemistry and Pathobiochemistry</orgName>
								<orgName type="institution">Otto-von-Guericke University Magdeburg</orgName>
								<address>
									<settlement>Magdeburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Clemens</forename><surname>Wittenbecher</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition PotsdameRehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">German Center for Diabetes Research (DZD)</orgName>
								<address>
									<settlement>München-Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Krasimira</forename><surname>Aleksandrova</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="laboratory">Nutrition, Immunity and Metabolism Start-up Lab</orgName>
								<orgName type="institution">German Institute of Human Nutrition Potsdam-Rehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition Potsdam-Rehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tobias</forename><surname>Pischon</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Molecular Epidemiology Group</orgName>
								<orgName type="department" key="dep2">Max Delbrück Center for Molecular Medicine (MDC)</orgName>
								<address>
									<settlement>Berlin-Buch, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">German Center for Cardiovascular Disease (DZHK)</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Fritsche</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">German Center for Diabetes Research (DZD)</orgName>
								<address>
									<settlement>München-Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Division of Endocrinology</orgName>
								<orgName type="department" key="dep3">Vascular Disease and Clinical Chemistry</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Diabetology, Tübingen</settlement>
									<region>Nephrology</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><forename type="middle">B</forename><surname>Schulze</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition PotsdameRehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">German Center for Diabetes Research (DZD)</orgName>
								<address>
									<settlement>München-Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">German Center for Cardiovascular Disease (DZHK)</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heiner</forename><surname>Boeing</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition Potsdam-Rehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Berend</forename><surname>Isermann</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute for Clinical Chemistry and Pathobiochemistry</orgName>
								<orgName type="institution">Otto-von-Guericke University Magdeburg</orgName>
								<address>
									<settlement>Magdeburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cornelia</forename><surname>Weikert</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Research Group Cardiovascular Epidemiology</orgName>
								<orgName type="institution">German Institute of Human Nutrition Potsdam-Rehbruecke</orgName>
								<address>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute for Social Medicine, Epidemiology and Health Economics</orgName>
								<orgName type="institution">Charit e University Medical Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">German Center for Cardiovascular Disease (DZHK)</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Food Safety</orgName>
								<orgName type="institution">Federal Institute for Risk Assessment</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Department of Molecular Epidemiology</orgName>
								<orgName type="institution">German Insti-tute of Human Nutrition PotsdameRehbruecke</orgName>
								<address>
									<addrLine>Arthur-Scheunert-Allee 114-116</addrLine>
									<postCode>14558</postCode>
									<settlement>Nuthetal</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Omentin-1 and risk of myocardial infarction and stroke: Results from the EPIC-Potsdam cohort study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-02">2 June 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">7A67B1DD7215145D10332188DD73D7D9</idno>
					<idno type="DOI">10.1016/j.atherosclerosis.2016.06.003</idno>
					<note type="submission">Received 18 February 2016 Received in revised form 20 May 2016 Accepted 1 June 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Adipokines Intelectin-1 Risk factor Adiponectin</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background and aims:</head><p><s>The recently identified adipokine omentin-1 is inversely associated with body fatness, metabolic syndrome and cardiovascular disease (CVD) in cross-sectional analyses.</s><s>However, prospective data on the association between plasma omentin-1 levels and future risk of CVD are lacking.</s><s>The aim of the study was to investigate the relationship between omentin-1 and incident myocardial infarction (MI) and stroke.</s><s>Methods: We conducted a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort comprising a subsample of 2084 participants, including 50 CVD cases and 350 external incident CVD cases (mean follow-up of 8.2 ± 1.6 years).</s><s>Prentice modified Cox regression adjusted for established CVD risk factors was used to estimate associations between omentin-1 and risk of MI and stroke, interactions were tested with cross-product terms.</s><s>Results: After multivariable adjustment, omentin-1 was not significantly associated with risk of MI (HR per doubling omentin-1:1.17;</s><s>95%-CI:0.79e1.72;</s><s>p ¼ 0.43), but with higher risk of stroke (HR per doubling omentin-1:2.22;</s><s>95%-CI:1.52e3.22;</s><s>p &lt; 0.0001).</s><s>In subgroup analyses, associations between omentin-1 and stroke risk were generally stronger in lower versus higher CVD risk groups.</s><s>For example, risk of stroke was stronger in participants without metabolic syndrome (HR per doubling omentin-1:2.58;</s><s>95%-CI:1.64e4.07;</s><s>p &lt; 0.0001) compared to those with metabolic syndrome (HR per doubling omentin-1:1.21;</s><s>95%-CI:0.59e2.50;</s><s>p ¼ 0.60) (p for interaction ¼ 0.05).</s><s>Similar interactions were observed when participants were classified in low or high risk groups according to waist circumference, triglyceride, hsCRP or adiponectin levels.</s><s>Conclusions: Omentin-1 concentrations may be related to increased stroke risk.</s><s>This association is stronger in metabolically healthy individuals.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Omentin-1, also referred to intelectin-1 or intestinal lactoferrin receptor ITLN1, was discovered as novel fat depot-specific secretory protein from a human omental fat cDNA library <ref type="bibr" target="#b0">[1]</ref>.</s><s>This adipokine is mainly expressed in visceral adipose stromal vascular cells, rather than in subcutaneous adipose, but also in lung, heart, placenta, and ovary tissue <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>Omentin occurs in two highly homologous isoforms of omentin-1 and omentin-2, but omentin-1 has been shown to be the major circulating isoform in human plasma <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Recent studies have observed that omentin-1 is inversely related to body mass index and waist circumference <ref type="bibr" target="#b2">[3]</ref>.</s><s>Positive associations with adiponectin and high density lipoprotein (HDL) cholesterol were also reported <ref type="bibr" target="#b2">[3]</ref>.</s><s>Based on these reported relationships, a possible protective role of omentin-1 in the pathogenesis of atherosclerosis and risk of CVD has been hypothesized.</s></p><p><s>However, to date, mainly cross-sectional studies investigated the relationship between omentin-1 and cardiovascular endpoints, often performed in patients with preexisting diseases <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>For example Lui et al. found an inverse association between omentin-1 levels and carotid artery intima-media thickness in patients with metabolic syndrome (MetS) <ref type="bibr" target="#b3">[4]</ref>.</s><s><ref type="bibr">Greulich et al.</ref> suggested that decreased omentin-1 levels were associated with cardiovascular dysfunction in patients with type 2 diabetes <ref type="bibr" target="#b4">[5]</ref>.</s><s>Moreover, patients with coronary artery disease (CAD) had lower omentin-1 levels [6e10].</s></p><p><s>Prospective studies investigating the relationship between omentin-1 and CVD incidence in apparently healthy participants are still missing.</s><s>Therefore, our study aimed to investigate the longitudinal association between circulating omentin-1 concentrations and risk of myocardial infarction (MI) and stroke in apparently healthy men and women of the EPIC-Potsdam study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Study population</head><p><s>The European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study consists of 16 644 women and 10 904 men recruited between 1994 and 1998 from the general population in Potsdam and surroundings <ref type="bibr" target="#b10">[11]</ref>.</s></p><p><s>About every 2 years, information on incident diseases was collected.</s><s>To identify potential CVD cases several sources were used: self-report, death certificate or linkage with hospital information system.</s><s>To increase sensitivity, the questionnaire included additional questions about typical stroke symptoms [12e14].</s><s>All identified potential CVD events were ascertained by study physicians, in cooperation with the patients' attending physicians and hospitals, who provided a detailed medical verification of selfreports and death certificates by clinical records according to the World Health Organization Monitoring of Trends and Determinants in Cardiovascular Disease criteria <ref type="bibr" target="#b14">[15]</ref>.</s><s>According to the International Statistical Classification of Diseases, 10th Revision (ICD-10), cases were classified as incident MI (ICD-10 I21), ischemic stroke (IS) (ICD-10 I63.0 to I63.9), hemorrhagic stroke (ICD-10 I60.0 to I61.9) or undetermined stroke (ICD-10 I64.0-I64.9)</s><s><ref type="bibr" target="#b15">[16]</ref>.</s><s>All verified incident cases of MI and stroke up to December 2008 were included.</s></p><p><s>A case-cohort design was applied, using all incident CVD cases and a subcohort of 2500 individuals randomly drawn from all participants of the EPIC-Potsdam study, who provided blood (n ¼ 26 444).</s><s>This design enables efficient analyses according to time and costs, whereas the results are expected to be generalizable without the need to measure biomarker levels in the entire cohort <ref type="bibr" target="#b16">[17]</ref>.</s><s>After exclusion of individuals with prevalent stroke or MI (n ¼ 85), missing follow-up data (n ¼ 53), inappropriate blood sample (n ¼ 213), missing covariates (n ¼ 107) and unreliable omentin-1 measurements (n ¼ 86), the final study population consisted of a subcohort of 2084 participants, including 50 CVD cases, and 350 verified external incident CVD cases that occurred during 8.2 ± 1.6 years of follow-up (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Participants gave their written informed consent, and study procedures were approved by the Ethics Committee of the Medical Association of the State of Brandenburg.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Assessment of risk factors and covariates</head><p><s>Lifestyle characteristics, including physical exercise, education and smoking history, were documented at baseline by trained interviewers during a computer-assisted interview <ref type="bibr" target="#b10">[11]</ref>.</s><s>History of hypertension was defined as systolic blood pressure !140 mmHg or diastolic blood pressure !90 mmHg, self-reports or use of antihypertensive medication.</s><s>The history of diabetes was evaluated by the study physician using information on self-reported diagnosis, medication records and dieting behavior.</s><s>Dietary habits including alcohol consumption were assessed by a validated food frequency questionnaire <ref type="bibr" target="#b10">[11]</ref>.</s><s>4.1%, inter-assay coefficients of variation between 4.4% and 4.8%) with a limit of detection of 0.5 ng/ml, according to the manufacturer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Blood collection and laboratory analysis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Statistical analysis</head><p><s>A multivariable adjusted analysis of covariance was performed to investigate associations between omentin-1 concentrations and several cardiovascular risk factors across quartiles of omentin-1 concentrations within the subcohort.</s></p><p><s>Prentice modified Cox proportional-hazards regression was used to estimate the associations between omentin-1 and risk of MI, stroke or its subtypes.</s><s>Age was used as underlying time axis with ''entry time'' defined as age at baseline and ''exit time'' as age at diagnosis of MI or stroke or censoring.</s><s>Hazard ratios (HR) were adjusted for sex and age (Model 1), waist circumference, smoking, physical activity, education, alcohol consumption, prevalent hypertension, prevalent diabetes, HDL-cholesterol, total cholesterol, triglycerides and hsCRP (Model 2), and adiponectin (Model 3).</s><s>Alcohol consumption, triglycerides, hsCRP and adiponectin were natural log transformed.</s><s>For linear relationship, on a continuous scale, omentin-1 was base 2 logarithm transformed, enabling the interpretation of increasing CVD risk per doubling of omentin-1 values.</s><s>The risk of MI and stroke was furthermore evaluated according to quartiles of omentin-1 using the first quartile as reference.</s></p><p><s>Competing risk analysis, as described by Lunn and McNeil <ref type="bibr" target="#b17">[18]</ref>, was applied to test whether the associations of omentin-1 differed between MI and stroke, and additionally between ischemic and hemorrhagic stroke.</s></p><p><s>Possible nonlinear relationships were examined with restricted cubic splines (RCS) with five knots at the 5th, 35th, 50th (reference), 65th and 95th percentile of omentin-1 in the fully adjusted model.</s><s>The Wald chi-square test was used to select the best-fit model.</s></p><p><s>Effect modifications between selected CVD risk factors (dichotomous) and omentin-1 (continuous) in relation to MI and stroke risks were tested with cross-product terms in model 3. Stratified analyses were performed according to established cutoff points: waist circumference (women &lt;/! 88 cm; men &lt;/! 102 cm) <ref type="bibr" target="#b18">[19]</ref>, HDL-cholesterol (women &lt;/! 1.29 mmol/l; men &lt;/! 1.04 mmol/l) <ref type="bibr" target="#b18">[19]</ref>, triglycerides (&lt;/! 1.69 mmol/l) <ref type="bibr" target="#b18">[19]</ref>, hsCRP (&lt;/! 1.0 mg/l) <ref type="bibr" target="#b19">[20]</ref>.</s><s>For adiponectin the sex-specific median from the subcohort was used (women &lt;/! 9.14 mg/ml; men &lt;/! 5.98 mg/ml).</s></p><p><s>Metabolic syndrome was defined using the American Heart Association/National Heart, Lung and Blood Institute criteria <ref type="bibr" target="#b18">[19]</ref>.</s></p><p><s>The proportional hazard assumption was tested by a Kolmogorov-type supremum test.</s><s>No violation was found.</s><s>A pvalue &lt;0.05 was considered to be statistically significant, for interactions p-value was increased to 0.10.</s><s>Sensitivity analyses were performed after exclusion of first 2 years of follow-up, to account for the latency period between pathology and clinical diagnosis.</s><s>Additionally Cox proportional-hazards regression analyses were applied to estimate the associations between omentin-1 and risk of MI and stroke with further adjustment of antidiabetic medication, antihypertensive medication and lipid-lowering medication in model 2 and model 3.</s><s>All statistical analyses were performed using SAS software, version 9.4 (SAS institute, Cary, N.C., USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head><p><s>Participants with incident MI or stroke were older and more likely to be male compared to persons without CVD events (Supplemental Table <ref type="table" target="#tab_0">1</ref>).</s><s>After adjustment for age and sex, persons with CVD events at baseline were also more likely to be smokers and to have a history of diabetes and hypertension compared to those without CVD events (Supplemental Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Within the subcohort, a cross-sectional multivariable adjusted analysis of covariance across quartiles of omentin-1 showed significant positive associations with age, physical activity, and history of diabetes, HDL-cholesterol, adiponectin, and alcohol consumption, significant inverse associations were observed with waist circumference (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Participants in the highest quartile of omentin-1 levels had a significantly increased risk of stroke (Model 3, HR: 2.29; 95%-confidence interval (CI) 1.38e3.79;</s><s>p linear trend ¼ 0.0003) compared to participants in the lowest quartile (Table <ref type="table">2</ref>).</s><s>Positive associations were also observed when omentin-1 was modelled on a continuous scale (Model 3 per doubling of omentin-1, HR: 2.22; 95%-CI: 1.52e3.22;</s><s>p &lt; 0.0001).</s><s>Separated analyses showed increased risk of both ischemic and hemorrhagic stroke in the highest versus the lowest quartile of omentin-1 (Table <ref type="table">2</ref>).</s><s>However, no relationship was observed between omentin-1 and risk of MI (Table <ref type="table">2</ref> and Fig. <ref type="figure" target="#fig_1">2</ref>).</s></p><p><s>In a competing risk analysis, a significant difference in the association between omentin-1 and MI versus omentin-1 and stroke was detected (p ¼ 0.02).</s><s>However, no difference was observed in the associations between omentin-1 and ischemic stroke versus omentin-1 and hemorrhagic stroke (p ¼ 0.43).</s></p><p><s>There was no evidence of departure from linearity for the relation between omentin-1 and stroke risk (p for nonlinearity ¼ 0.82).</s><s>We found no significant non-linear associations between omentin-1 and risk of MI (Fig. <ref type="figure" target="#fig_1">2</ref>).</s></p><p><s>Stratified analyses according to CVD risk subgroups showed an association between omentin-1 and increased stroke risk in particular in metabolically healthy individuals.</s><s>As presented in Table <ref type="table" target="#tab_1">3</ref>, in participants with high adiponectin levels higher omentin-1 levels were related to a higher risk of stroke (HR per doubling omentin-1: 3.52; 95%-CI: 2.08e5.94;</s><s>p &lt; 0.0001), and omentin-1 was not associated with stroke risk in participants with low adiponectin levels (HR per doubling omentin-1: 1.14, 95%-CI: 0.65e2.01,</s><s>p ¼ 0.65) (p for interaction ¼ 0.02).</s><s>Furthermore, risk of stroke was stronger in participants without MetS (HR per doubling omentin-1: 2.58; 95%-CI: 1.64e4.07;</s><s>p &lt; 0.0001) compared to those with MetS (HR per doubling omentin-1: 1.21; 95%-CI: 0.59e2.50;</s><s>p ¼ 0.60) (p for interaction ¼ 0.05).</s><s>Similar interactions were observed when participants were classified in low or high risk groups according to waist circumference (p for interaction ¼ 0.03), triglyceride (p for interaction ¼ 0.09) or hsCRP (p for interaction ¼ 0.08).</s><s>According to MI risk, stratified analyses showed a decreased MI risk in participants with MetS and a stronger MI risk in individuals without MetS (p for interaction ¼ 0.02), though both associations were not statistically significant (Supplemental Table <ref type="table">2</ref>).</s></p><p><s>After exclusion of cases that occurred during the first 2 years of follow-up, the hazard ratios of stroke and MI according to omentin-1 concentrations remained unaltered (data not shown).</s><s>Further, we observed no changes in results with additionally adjustment of antidiabetic medication, antihypertensive medication and lipidlowering medication in the main multivariable analysis (Model 2 and Model 3, data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>In this prospective analysis, we observed that higher levels of omentin-1 were significantly associated with a higher risk of stroke in metabolically healthy participants with normal waist circumference, low levels of triglyceride and hsCRP, high adiponectin levels and no MetS.</s><s>On the contrary, omentin-1 was not significantly related to risk of MI.</s></p><p><s>To our knowledge, this is the first prospective study investigating potential associations between omentin-1 and risk of stroke and MI in apparently healthy middle aged men and women.</s><s>So far, only two small prospective studies investigated the association between omentin-1 and cardiovascular endpoints in patients with heart disease, providing conflicting findings <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>In line with our study, Saely et al. reported an association between higher plasma omentin-1 levels and higher risk of cardiovascular events in 295 CAD patients <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s>In contrast, in a study comprising 136 patients with heart failure, Narumi and colleagues observed an association between lower omentin-1 levels and higher risk of cardiac death or re-hospitalization <ref type="bibr" target="#b20">[21]</ref>.</s></p><p><s>Results from cross-sectional studies suggested omentin-1 as a potential cardio-protective factor, inversely related to cardiovascular risk factors and intermediates.</s><s>Interestingly, cross-sectional analyses from our study are in line with previous studies providing additional evidence regarding cross-sectional associations between omentin-1 and lifestyle factors, blood lipids and adiponectin.</s><s>Our study supports recently reported inverse association between omentin-1 and waist circumference <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>Moreover, we observed a positive association between omentin-1 and HDL-cholesterol <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25]</ref> as well as a positive association between omentin-1 and adiponectin consistent with previous studies <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>In line, also relations between omentin-1 and clinical intermediate cardiovascular phenotypes were observed.</s><s>Crosssectional studies including patients with type 2 diabetes or MetS, observed inverse associations between omentin-1 and arterial stiffness/carotid plaque as well as left ventricular diastolic function <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b26">27]</ref>.</s><s>Moreover, Lui et al. reported an inverse relation between omentin-1 levels and carotid artery intima-media thickness in MetS patients <ref type="bibr" target="#b3">[4]</ref>.</s><s>Nevertheless, these findings were observed in studies comprising low number of participants with existing diseases.</s><s>Interestingly, restricting our results to a subgroup of  participants with MetS we also observed an inverse, though nonsignificant, association between omentin-1 and risk of MI.</s><s>Therefore we may hypothesize that the role of omentin-1 in metabolic regulation probably systematically differs in participants with preexisting metabolic disease as compared to those apparently healthy.</s><s>However, the suggested protective effect was not observed in stratified analysis regarding risk of stroke, although a lower risk in participants with MetS was observed, compared to participants without MetS.</s><s>With regard to stroke risk, we observed a significant positive interaction between omentin-1 and waist circumference as well as between omentin-1 and adiponectin.</s><s>Interestingly, adiponectin and omentin-1 share the same pattern of physiological effects i.e. both are downregulated in obesity <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b27">28]</ref>, both have been proposed to have a beneficial effect on glucose metabolism and insulin sensitivity <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b28">29]</ref>, and both were discussed as cardio-protective adipokines <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b29">30]</ref>.</s><s>However, the association between omentin-1 and stroke risk was particularly strong among individuals with high adiponectin levels compared to those with low levels.</s><s>Therefore, a complex molecular interplay between omentin-1 and adiponectin in relation to risk of stroke might be hypothesized.</s><s>Yet, the available evidence is insufficient to infer a possible mechanism explaining the observed interaction between omentin-1 and adiponectin.</s><s>To date, it is uncertain whether the regulation of omentin-1 may be dependent on adiponectin or vice versa <ref type="bibr" target="#b2">[3]</ref>.</s><s>So far, only Herder et al. have hypothesized that circulating omentin-1 levels regulate adiponectin levels <ref type="bibr" target="#b23">[24]</ref>.</s></p><p><s>Up to date, experimental studies have suggested omentin-1 as a potential cardio-protective factor [31e37].</s><s>Yamawaki et al. have shown that omentin-1 may enhance vasodilation in vascular endothelial cells vessels through endothelium-derived nitric oxide <ref type="bibr" target="#b30">[31]</ref>.</s><s>In addition, omentin-1 has been suggested to increase AMPactivated protein kinase (AMPK) phosphorylation, and to promote endothelial cell function e.g.</s><s>enhancement of endothelial cell differentiation <ref type="bibr" target="#b31">[32]</ref>, protection of cardiac myocytes from apoptosis during ischemia <ref type="bibr" target="#b32">[33]</ref> and attenuate neointimal formation after arterial injury in vivo <ref type="bibr" target="#b33">[34]</ref>.</s><s>Furthermore, omentin-1 may exert antiinflammatory functions via AMPK signaling pathway [35e37].</s></p><p><s>However, as already mentioned in line with our study results, recently another prospective study by Sealy et al. refuted the suggested cardio-protective associations and in addition demonstrates that omentin-1 strongly predicts cardiovascular events <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s>Yet, the reasons for such discrepant findings are unclear, demonstrating that the biological action of omentin-1 in the cardiovascular biology is hardly understood.</s><s>So far, we might speculate, somehow, an omentin-1-related stroke risk depended from different metabolic conditions e.g.</s><s>high or low level of adiponectin, triglycerides or hsCRP.</s><s>Competition for possible shared signal pathways with different signaling efficiencies would in principle agree with our observations.</s><s>We suspect a molecular interplay between omentin-1 and other CVD risk factors to be of complex nature and to be probably altered in the pathophysiological context.</s></p><p><s>However, given the strong associations between higher omentin-1 levels and stroke risk on the one hand and the nonsignificant relation with MI on the other hand, intense research and well-designed experiments are needed, addressing the biological processes of omentin-1 with the risk of different major cardiovascular endpoints under different metabolic conditions.</s></p><p><s>Strengths of the current study include the prospective study design, the availability of high quality data as a result of the standardized procedures enabling us to adjust for a large variety of potential confounders, the high follow-up response rate, and the rigorous case validation.</s><s>Nevertheless, the present results are limited to middle aged Caucasian participants and might be not generalized to other ethnic groups.</s><s>The competing risk analyses revealed no significant differences in the association omentin-1 and ischemic stroke compared to hemorrhagic stroke, but based on the limited number of cases, in particular for hemorrhagic stroke, a chance finding cannot be completely ruled out.</s><s>Furthermore, the present findings are based on one single baseline measurement of omentin-1 levels with long-term sample storage.</s><s>Nevertheless, EPIC-Potsdam provides high quality blood samples, because of the highly standardized processes for sample collection and storing.</s><s>Plasma samples used for omentin-1 assessment were stored at À80 C in freezers, a temperature that guarantees the stability of samples for long periods of time for a wide range of analytes, including highly labile molecules such as cytokines <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39]</ref>.</s><s>Moreover, we observed excellent reliability of omentin-1 over time indicated by intraclass correlation coefficient (ICC) of 0.83 (95%-CI 0.78e0.87),</s><s>which was very similar to the ICC reported from a previous study <ref type="bibr" target="#b39">[40]</ref>, suggesting that a single measurement may provide reliable risk estimates <ref type="bibr" target="#b40">[41]</ref>.</s></p><p><s>In conclusion, the current study observed that high plasma omentin-1 concentrations were associated with a higher risk of stroke in particular in participants with normal waist circumference, low levels of triglyceride and hsCRP, high adiponectin levels or no metabolic syndrome.</s><s>Further studies are needed to explain the different role of omentin-1 under different metabolic conditions.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Flow diagram.</s><s>Flow diagram for the exclusion criteria indicating the number of subjects excluded and those remaining for the main analysis.</s></p></div></figDesc><graphic coords="2,304.72,486.09,245.25,232.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Hazard ratio curves.</s><s>(A) Hazard ratio curves for the association between omentin-1 levels and the risk of stroke.</s><s>(B) Hazard ratio curves for the association between omentin-1 levels and the risk of MI.</s><s>The solid lines indicate hazard ratios of stroke or MI as obtained by restricted cubic spline Cox regression with knots placed at fixed values (5th, 35th, 65th and 95th percentile of the distribution of omentin-1 in the entire case-cohort).</s><s>The reference was set at 50th percentile.</s><s>Dashed lines indicate 95%-CI.</s><s>Hazard ratios and 95%-CI bands are adjusted for age, sex, waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol, total cholesterol, triglycerides, hsCRP, adiponectin.</s><s>P for nonlinearity was computed by Wald chi-square test.</s></p></div></figDesc><graphic coords="5,45.41,66.73,245.25,287.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Characteristics of the subcohort according to omentin-1 quartiles.</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell></cell><cell cols="4">Quartiles of omentin-1 in the subcohort a</cell><cell></cell><cell></cell><cell>p linear trend c</cell><cell>p linear trend d</cell></row><row><cell></cell><cell></cell><cell>Q1</cell><cell></cell><cell>Q2</cell><cell></cell><cell>Q3</cell><cell></cell><cell>Q4</cell></row><row><cell>n</cell><cell></cell><cell>519</cell><cell></cell><cell>525</cell><cell></cell><cell>519</cell><cell></cell><cell>521</cell></row><row><cell>Omentin-1 [ng/ml] b</cell><cell></cell><cell cols="2">286.5 (250.6e308.6)</cell><cell cols="2">363.1 (343.4e380.3)</cell><cell cols="2">439.6 (420.0e462.8)</cell><cell>569.6 (517.4e642.6)</cell></row><row><cell>Men [%] c</cell><cell></cell><cell>41.2</cell><cell></cell><cell>36.6</cell><cell></cell><cell>37.7</cell><cell></cell><cell>33.5</cell><cell>0.02</cell><cell>0.1</cell></row><row><cell>Age [years] c</cell><cell></cell><cell>47.4 (46.6e48.1)</cell><cell></cell><cell cols="2">48.8 (48.1e49.5)</cell><cell cols="2">51.9 (51.1e52.6)</cell><cell>53.9 (53.2e54.6)</cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>Waist circumference [cm]</cell><cell></cell><cell>89.8 (88.8e90.7)</cell><cell></cell><cell cols="2">87.4 (86.5e88.3)</cell><cell cols="2">86.6 (85.7e87.5)</cell><cell>85.1 (84.2e86.0)</cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>Physical activity, [h/week]</cell><cell></cell><cell>0.88 (0.73e1.03)</cell><cell></cell><cell cols="2">0.91 (0.76e1.05)</cell><cell cols="2">0.98 (0.83e1.13)</cell><cell>1.26 (1.11e1.41)</cell><cell>0.0005</cell><cell>0.01</cell></row><row><cell>Smoking [%]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.3</cell><cell>0.5</cell></row><row><cell>Non-smoker</cell><cell></cell><cell>43.1</cell><cell></cell><cell>43.3</cell><cell></cell><cell>40.7</cell><cell></cell><cell>46.9</cell></row><row><cell>Ex-smoker &lt; 5 years</cell><cell></cell><cell>26.1</cell><cell></cell><cell>27.3</cell><cell></cell><cell>28.4</cell><cell></cell><cell>24.8</cell></row><row><cell>Ex-smoker ! 5 years</cell><cell></cell><cell>7.4</cell><cell></cell><cell>6.4</cell><cell></cell><cell>8.7</cell><cell></cell><cell>8.9</cell></row><row><cell>Smoker &lt; 20 cigarettes/day</cell><cell></cell><cell>16.0</cell><cell></cell><cell>14.9</cell><cell></cell><cell>17.2</cell><cell></cell><cell>12.6</cell></row><row><cell cols="2">Smoker ! 20 cigarettes/day</cell><cell>7.3</cell><cell></cell><cell>8.1</cell><cell></cell><cell>4.9</cell><cell></cell><cell>6.8</cell></row><row><cell>Education [%]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.7</cell><cell>0.4</cell></row><row><cell>Unskilled or skilled</cell><cell></cell><cell>35.4</cell><cell></cell><cell>35.0</cell><cell></cell><cell>35.2</cell><cell></cell><cell>35.4</cell></row><row><cell>Technical College</cell><cell></cell><cell>22.4</cell><cell></cell><cell>23.5</cell><cell></cell><cell>23.5</cell><cell></cell><cell>21.3</cell></row><row><cell>University degree</cell><cell></cell><cell>42.2</cell><cell></cell><cell>41.5</cell><cell></cell><cell>41.2</cell><cell></cell><cell>43.3</cell></row><row><cell>Prevalent diabetes [%]</cell><cell></cell><cell>3.7</cell><cell></cell><cell>3.8</cell><cell></cell><cell>4.6</cell><cell></cell><cell>5.9</cell><cell>0.07</cell><cell>0.0004</cell></row><row><cell>Antidiabetic medication [%]</cell><cell></cell><cell>1.6</cell><cell></cell><cell>1.6</cell><cell></cell><cell>3.1</cell><cell></cell><cell>3.2</cell><cell>0.03</cell><cell>0.0004</cell></row><row><cell>Prevalent hypertension [%]</cell><cell></cell><cell>50.7</cell><cell></cell><cell>48.7</cell><cell></cell><cell>47.4</cell><cell></cell><cell>49.6</cell><cell>0.6</cell><cell>0.06</cell></row><row><cell cols="2">Antihypertensive medication [%]</cell><cell>19.4</cell><cell></cell><cell>16.0</cell><cell></cell><cell>16.6</cell><cell></cell><cell>19.0</cell><cell>0.9</cell><cell>0.07</cell></row><row><cell cols="2">Lipid-lowering medication [%]</cell><cell>4.7</cell><cell></cell><cell>4.4</cell><cell></cell><cell>3.6</cell><cell></cell><cell>4.0</cell><cell>0.5</cell><cell>0.5</cell></row><row><cell>Total cholesterol [mmol/l]</cell><cell></cell><cell>5.24 (5.15e5.33)</cell><cell></cell><cell cols="2">5.26 (5.17e5.36)</cell><cell cols="2">5.26 (5.17e5.35)</cell><cell>5.37 (5.27e5.46)</cell><cell>0.08</cell><cell>0.4</cell></row><row><cell>HDL-cholesterol [mmol/l]</cell><cell></cell><cell>1.36 (1.32e1.39)</cell><cell></cell><cell cols="2">1.39 (1.36e1.42)</cell><cell cols="2">1.41 (1.38e1.44)</cell><cell>1.53 (1.50e1.56)</cell><cell>&lt;0.0001</cell><cell>0.03</cell></row><row><cell>Triglyceride [mmol/l]</cell><cell></cell><cell>1.64 (1.55e1.73)</cell><cell></cell><cell cols="2">1.53 (1.44e1.62)</cell><cell cols="2">1.66 (1.57e1.75)</cell><cell>1.47 (1.37e1.56)</cell><cell>0.0003</cell><cell>0.7</cell></row><row><cell>hsCRP [mg/l]</cell><cell></cell><cell>2.57 (2.26e2.89)</cell><cell></cell><cell cols="2">1.67 (1.37e1.97)</cell><cell cols="2">1.89 (1.59e2.20)</cell><cell>1.64 (1.33e1.95)</cell><cell>&lt;0.0001</cell><cell>0.06</cell></row><row><cell>Adiponectin [mg/ml]</cell><cell></cell><cell>6.99 (6.67e7.32)</cell><cell></cell><cell cols="2">7.78 (7.46e8.10)</cell><cell cols="2">8.23 (7.90e8.55)</cell><cell>9.30 (8.97e9.63)</cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>Alcohol [g/d]</cell><cell></cell><cell>14.6 (12.9e16.3)</cell><cell></cell><cell cols="2">16.5 (14.8e18.2)</cell><cell cols="2">16.6 (14.9e18.2)</cell><cell>19.4 (17.7e21.1)</cell><cell>&lt;0.0001</cell><cell>0.0004</cell></row><row><cell>Table 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">Hazard ratios of MI and stroke according to quartiles and per doubling of omentin-1 levels.</cell><cell></cell></row><row><cell></cell><cell cols="3">Quartiles of omentin-1 levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>p for trend</cell><cell>Per doubling of omentin-1</cell></row><row><cell></cell><cell>Q1</cell><cell></cell><cell>Q2</cell><cell></cell><cell>Q3</cell><cell></cell><cell>Q4</cell><cell>p-value</cell></row><row><cell>Omentin-1 [ng/ml] a</cell><cell cols="2">286.5 (250.6e307.4)</cell><cell cols="2">364.2 (344.0e380.5)</cell><cell cols="2">439.6 (420.0e462.2)</cell><cell cols="2">571.9 (519.5e642.6)</cell></row><row><cell>Subcohort participants (n)</cell><cell>519</cell><cell></cell><cell>525</cell><cell></cell><cell>519</cell><cell></cell><cell>521</cell></row><row><cell>Follow-up time [years]</cell><cell>4245.8</cell><cell></cell><cell>4288.9</cell><cell></cell><cell>4304.1</cell><cell></cell><cell>4234.2</cell></row><row><cell>MI (n ¼ 2267)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cases (n)</cell><cell>43</cell><cell></cell><cell>45</cell><cell></cell><cell>54</cell><cell></cell><cell>60</cell></row><row><cell>Sex and age adjusted</cell><cell cols="2">Reference</cell><cell cols="2">0.99 (0.63e1.54)</cell><cell cols="2">0.91 (0.60e1.39)</cell><cell cols="2">0.95 (0.62e1.45)</cell><cell>0.80</cell><cell>0.96 (0.68e1.35)</cell><cell>0.79</cell></row><row><cell>Model 2 b</cell><cell cols="2">Reference</cell><cell cols="2">0.90 (0.56e1.44)</cell><cell cols="2">0.97 (0.62e1.51)</cell><cell cols="2">1.16 (0.73e1.83)</cell><cell>0.42</cell><cell>1.19 (0.81e1.75)</cell><cell>0.37</cell></row><row><cell>Model 3 c</cell><cell cols="2">Reference</cell><cell cols="2">0.89 (0.56e1.42)</cell><cell cols="2">0.96 (0.61e1.50)</cell><cell cols="2">1.13 (0.71e1.79)</cell><cell>0.48</cell><cell>1.17 (0.79e1.72)</cell><cell>0.43</cell></row><row><cell>Stroke (n ¼ 2251)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cases (n)</cell><cell>24</cell><cell></cell><cell>34</cell><cell></cell><cell>55</cell><cell></cell><cell>85</cell></row><row><cell>Sex and age adjusted</cell><cell cols="2">Reference</cell><cell cols="2">1.29 (0.75e2.23)</cell><cell cols="2">1.73 (1.05e2.84)</cell><cell cols="2">2.39 (1.50e3.82)</cell><cell>&lt;0.0001</cell><cell>2.12 (1.54e2.92)</cell><cell>&lt;0.0001</cell></row><row><cell>Model 2 b</cell><cell cols="2">Reference</cell><cell cols="2">1.26 (0.72e2.20)</cell><cell cols="2">1.63 (0.97e2.73)</cell><cell cols="2">2.42 (1.47e3.98)</cell><cell>0.0001</cell><cell>2.31 (1.59e3.35)</cell><cell>&lt;0.0001</cell></row><row><cell>Model 3 c</cell><cell cols="2">Reference</cell><cell cols="2">1.24 (0.71e2.16)</cell><cell cols="2">1.58 (0.94e2.66)</cell><cell cols="2">2.29 (1.38e3.79)</cell><cell>0.0003</cell><cell>2.22 (1.52e3.22)</cell><cell>&lt;0.0001</cell></row><row><cell>Ischemic stroke (n ¼ 2218)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cases (n)</cell><cell>19</cell><cell></cell><cell>29</cell><cell></cell><cell>45</cell><cell></cell><cell>68</cell></row><row><cell>Sex and age adjusted</cell><cell cols="2">Reference</cell><cell cols="2">1.37 (0.75e2.51)</cell><cell cols="2">1.73 (1.00e3.02)</cell><cell cols="2">2.31 (1.37e3.90)</cell><cell>0.0006</cell><cell>1.96 (1.38e2.79)</cell><cell>0.0002</cell></row><row><cell>Model 2 b</cell><cell cols="2">Reference</cell><cell cols="2">1.34 (0.72e2.47)</cell><cell cols="2">1.59 (0.89e2.85)</cell><cell cols="2">2.34 (1.34e4.10)</cell><cell>0.001</cell><cell>2.13 (1.41e3.20)</cell><cell>0.0003</cell></row><row><cell>Model 3 c</cell><cell cols="2">Reference</cell><cell cols="2">1.32 (0.71e2.43)</cell><cell cols="2">1.54 (0.86e2.76)</cell><cell cols="2">2.20 (1.25e3.86)</cell><cell>0.003</cell><cell>2.02 (1.34e3.05)</cell><cell>0.0008</cell></row><row><cell cols="2">Hemorrhagic stroke (n ¼ 2114)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cases (n)</cell><cell>4</cell><cell></cell><cell>5</cell><cell></cell><cell>10</cell><cell></cell><cell>15</cell></row><row><cell>Sex and age adjusted</cell><cell cols="2">Reference</cell><cell cols="2">1.23 (0.33e4.63)</cell><cell cols="2">2.19 (0.70e6.90)</cell><cell cols="2">3.18 (1.06e9.55)</cell><cell>0.009</cell><cell>2.62 (1.43e4.79)</cell><cell>0.002</cell></row><row><cell>Model 2 b</cell><cell cols="2">Reference</cell><cell cols="2">1.32 (0.35e4.97)</cell><cell cols="2">2.28 (0.74e7.05)</cell><cell cols="2">3.46 (1.11e10.8)</cell><cell>0.01</cell><cell>2.85 (1.43e5.68)</cell><cell>0.003</cell></row><row><cell>Model 3 c</cell><cell cols="2">Reference</cell><cell cols="2">1.30 (0.35e4.91)</cell><cell cols="2">2.28 (0.74e7.04)</cell><cell cols="2">3.37 (1.08e10.6)</cell><cell>0.01</cell><cell>2.80 (1.39e5.62)</cell><cell>0.004</cell></row></table><note><p><s>a All variables were adjusted for sex and age, expressed as adjusted percentage or mean and 95%-CI.bUnadjusted</s><s>variable, expressed as median and interquartile range.cAdjusted</s><s>for sex, age; according to examined variable.dMutually</s><s>adjusted for sex, age, waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol, total cholesterol, triglycerides, hsCRP and adiponectin according to examined variable.Hazard ratios and 95%-CI were derived from Cox proportional hazard regression.a</s><s>Quartiles are based on the distribution of omentin-1 within the subcohort expressed as median and interquartile range.</s><s>b Additionally adjusted for waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol, total cholesterol, triglycerides and hsCRP.</s><s>c Additionally adjusted for adiponectin levels.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 3</head><label>3</label><figDesc><div><p><s>Multivariable adjusted hazard ratios for stroke per doubling of omentin-1 for subgroups.</s></p></div></figDesc><table><row><cell>Group</cell><cell>Cases</cell><cell>Subcohort a</cell><cell>p for interaction b</cell><cell>Hazard ratio (95%-CI) c</cell><cell>p-value</cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell>0.68</cell><cell></cell><cell></cell></row><row><cell>Men</cell><cell>114</cell><cell>754</cell><cell></cell><cell>2.65 (1.55e4.52)</cell><cell>0.0004</cell></row><row><cell>Women</cell><cell>84</cell><cell>1299</cell><cell></cell><cell>1.90 (1.06e3.40)</cell><cell>0.03</cell></row><row><cell>Waist circumference [cm]</cell><cell></cell><cell></cell><cell>0.03</cell><cell></cell><cell></cell></row><row><cell>&lt; 102 men, &lt; 88 women</cell><cell>134</cell><cell>1569</cell><cell></cell><cell>2.59 (1.63e4.11)</cell><cell>&lt;0.0001</cell></row><row><cell>! 102 men, ! 88 women</cell><cell>64</cell><cell>484</cell><cell></cell><cell>1.76 (0.82e3.77)</cell><cell>0.15</cell></row><row><cell>Metabolic syndrome d</cell><cell></cell><cell></cell><cell>0.05</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>128</cell><cell>1649</cell><cell></cell><cell>2.58 (1.64e4.07)</cell><cell>&lt;0.0001</cell></row><row><cell>Yes</cell><cell>70</cell><cell>402</cell><cell></cell><cell>1.21 (0.59e2.50)</cell><cell>0.60</cell></row><row><cell>HDL-cholesterol [mmol/l]</cell><cell></cell><cell></cell><cell>0.49</cell><cell></cell><cell></cell></row><row><cell>&lt; 1.04 men, &lt; 1.29 women</cell><cell>55</cell><cell>490</cell><cell></cell><cell>2.76 (1.23e6.17)</cell><cell>0.01</cell></row><row><cell>! 1.04 men, ! 1.29 women</cell><cell>143</cell><cell>1563</cell><cell></cell><cell>2.16 (1.38e3.38)</cell><cell>0.0007</cell></row><row><cell>Triglycerides [mmol/l]</cell><cell></cell><cell></cell><cell>0.09</cell><cell></cell><cell></cell></row><row><cell>&lt; 1.69</cell><cell>123</cell><cell>1480</cell><cell></cell><cell>3.16 (1.90e5.25)</cell><cell>&lt;0.0001</cell></row><row><cell>! 1.69</cell><cell>75</cell><cell>573</cell><cell></cell><cell>1.28 (0.73e2.26)</cell><cell>0.39</cell></row><row><cell>Adiponectin [mg/ml]</cell><cell></cell><cell></cell><cell>0.02</cell><cell></cell><cell></cell></row><row><cell>&lt; 5.98 men, &lt; 9.14 women</cell><cell>91</cell><cell>1031</cell><cell></cell><cell>1.14 (0.65e2.01)</cell><cell>0.65</cell></row><row><cell>! 5.98 men, ! 9.14 women</cell><cell>107</cell><cell>1022</cell><cell></cell><cell>3.52 (2.08e5.94)</cell><cell>&lt;0.0001</cell></row><row><cell>hsCRP [mg/l]</cell><cell></cell><cell></cell><cell>0.08</cell><cell></cell><cell></cell></row><row><cell>&lt; 1.0</cell><cell>90</cell><cell>1165</cell><cell></cell><cell>2.98 (1.70e5.21)</cell><cell>0.0001</cell></row><row><cell>! 1.0</cell><cell>108</cell><cell>888</cell><cell></cell><cell>1.49 (0.83e2.66)</cell><cell>0.18</cell></row></table><note><p><s>a Subcohort without internal cases.b</s><s>p-values for interaction were calculated using dichotomous variables and log-transformed omentin-1 levels.c</s><s>Adjusted for age, sex, waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol, total cholesterol, triglycerides, hsCRP, adiponectin.d</s><s>n ¼ 2249 due to MetS missing values.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J. Menzel et al. / Atherosclerosis 251 (2016) 415e421</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank the Human Study Centre (HSC) of the German Institute of Human Nutrition Potsdam-Rehbrücke, namely the trustee and the examination unit for the collection, the data hub for the processing, and the participants for the provision of the data, the biobank for the processing of the biological samples and the head of the HSC, Manuela Bergmann, for the contribution to the study design and leading the underlying processes of data generation.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>The authors declared that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Financial support</head><p><s>This project was conducted within the framework of the topic field "Metabolische Dysfunktion und Volkserkrankungen, Teilprojekt: Metabolische Dysfunktion, Entzündungen und kardiovaskul€ are Krankheiten sowie metabolische Dysfunktionen und Tumorerkrankungen", supported by the Helmholtz Association.</s><s>Furthermore the study was supported by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix A. Supplementary data</head><p><s>Supplementary data related to this article can be found at http:// dx.doi.org/10.1016/j.atherosclerosis.2016.06.003.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Identification of omentin as a novel depotspecific adipokine in human adipose tissue: possible role in modulating insulin action</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Z</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Physiol. Endocrinol. Metab</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="E1253" to="E1261" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Omentin: a novel link between inflammation, diabesity, and cardiovascular disease</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Adya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Randeva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Cardiovasc. Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="143" to="e148" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Omentin plasma levels and gene expression are decreased in obesity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>De Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Z</forename><surname>Batista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1655" to="e1661" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome</title>
		<author>
			<persName><forename type="first">R</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Res. Clin. Pract</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="21" to="e25" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Greulich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Maxhera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e59697</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Association of serum omentin-1 levels with coronary artery disease</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Pharmacol. Sin</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="873" to="e878" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Shang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomarkers</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="657" to="e662" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women</title>
		<author>
			<persName><forename type="first">I</forename><surname>Onur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Oz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yildiz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Angiology</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="896" to="e900" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Circulating omentin is associated with coronary artery disease in men</title>
		<author>
			<persName><forename type="first">R</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ouchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kikuchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">219</biblScope>
			<biblScope unit="page" from="811" to="e814" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure, Asian Pac</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Z</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Trop. Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="55" to="e62" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">EPIC-GermanyeA source for studies into diet and risk of chronic diseases</title>
		<author>
			<persName><forename type="first">H</forename><surname>Boeing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wahrendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Becker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. Investig. Cancer Nutr. Ann. Nutr. Metab</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="195" to="e204" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke</title>
		<author>
			<persName><forename type="first">C</forename><surname>Weikert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Stefan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Schulze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="2555" to="e2562" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Joint effects of risk factors for stroke and transient ischemic attack in a German population: the EPIC Potsdam study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Weikert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heidemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurol</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page" from="315" to="e321" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Liver enzymes and stroke risk in middle-aged German adults</title>
		<author>
			<persName><forename type="first">C</forename><surname>Weikert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Drogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Di Giuseppe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">228</biblScope>
			<biblScope unit="page" from="508" to="e514" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tunstall-Pedoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kuulasmaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Amouyel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="583" to="e612" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">World Health Organization, International Statistical Classification of Diseases and Related Health Problems, World Health Organization</title>
		<imprint>
			<date type="published" when="1992">1992</date>
			<pubPlace>Geneva, Switzerland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A case-cohort design for epidemiologic cohort studies and disease prevention trials</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Prentice</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1" to="e11" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Applying Cox regression to competing risks</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcneil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="524" to="e532" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Grundy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Brewer</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Cleeman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Heart Association conference on scientific issues related to definition</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="433" to="e438" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Circulation</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Dunning III, Manual of laboratory and diagnostic tests</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Fischbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lippincott Williams Wilkins</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="642" to="e643" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure</title>
		<author>
			<persName><forename type="first">T</forename><surname>Narumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kadowaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">84</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Saely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leiherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muendlein</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.atherosclerosis.2015.10.100</idno>
		<ptr target="http://dx.doi.org/10.1016/j.atherosclerosis.2015.10.100" />
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Coronary patients with high plasma omentin are at a higher cardiovascular risk</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Saely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leiherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muendlein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Data Brief</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="158" to="e161" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: results from the KORA F4 study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Herder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Ouwens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carstensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Endocrinol./Eur. Fed. Endocr. Soc</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="423" to="e432" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome</title>
		<author>
			<persName><forename type="first">I</forename><surname>Jialal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Devaraj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kaur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Endocrinol. Metab</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="E514" to="E517" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Long</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="257" to="e263" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes, Cardiovasc Diabetol</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Hong</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">103</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Back to the heart: the protective role of adiponectin</title>
		<author>
			<persName><forename type="first">C</forename><surname>Caselli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>D'amico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cabiati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Res. Off. J. Ital. Pharmacol. Soc</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="9" to="e20" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Biomarkers of insulin sensitivity and insulin resistance: past, present and future</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sweeney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Clin. Lab. Sci</title>
		<imprint>
			<biblScope unit="page" from="1" to="e11" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Vanhoutte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Sci</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="361" to="e374" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yamawaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tsubaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mukohda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">393</biblScope>
			<biblScope unit="page" from="668" to="e672" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism</title>
		<author>
			<persName><forename type="first">S</forename><surname>Maruyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kikuchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="408" to="e417" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Omentin prevents myocardial ischemic injury through AMP-activated protein kinase-and Akt-dependent mechanisms</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kataoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Am. Coll. Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="2722" to="e2733" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Adipose-derived protein omentin prevents neointimal formation after arterial injury</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Uemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kanemura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="141" to="e151" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kazama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Usui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Okada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">686</biblScope>
			<biblScope unit="page" from="116" to="e123" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yamawaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuramoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kameshima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">408</biblScope>
			<biblScope unit="page" from="339" to="e343" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Role of anti-inflammatory adipokines in obesity-related diseases</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Murohara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Endocrinol. Metab. TEM</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="348" to="e355" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine</title>
		<author>
			<persName><forename type="first">P</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Peakman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">K</forename><surname>Biobank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="234" to="e244" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Callas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Jenny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thromb. Haemost</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="1495" to="e1500" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk</title>
		<author>
			<persName><forename type="first">G</forename><surname>Panagiotou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Na</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1265" to="e1271" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Reproducibility of retinol binding protein 4 and omentin-1 measurements over a four months period: a reliability study in a cohort of 207 apparently healthy participants</title>
		<author>
			<persName><forename type="first">C</forename><surname>Wittenbecher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Di Giuseppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Biemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0138480</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
